Podcasts about Biomarker

Have you ever wondered: What if, in those early days after diagnosis, there was something you could do to help protect the insulin your body still makes? In this episode, we're exploring exactly that. I'm joined by Ulf Hannelius, CEO of Diamyd Medical, to talk about a therapy that could be a game-changer for people newly diagnosed with type 1 diabetes. It's called GAD therapy, and it's currently being studied in the DIAGNODE-3 clinical trial. We dig into the science behind this investigational treatment and the hope it offers for preserving the body's remaining insulin production. Ulf not only explains the research in simple terms, but also shares his vision for the future of T1D. We know how overwhelming diabetes research can feel, but this is one conversation everyone in the T1D community should hear, especially if you or someone you love is facing a new diagnosis.Quick Takeaways:The latest research aiming to protect insulin production after a type 1 diabetes diagnosisA clear breakdown of Diamyd Medical's GAD therapy and the DIAGNODE-3 trial — what it is, who it's for, and why it offers hope for the future of T1DWhat's actually happening inside the body of someone newly diagnosed with type 1 diabetesDefining T1D terms you've probably heard but no one ever defines: Honeymoon phase, C-peptide, Stage 3 Type 1 Diabetes, Antigen-specific therapy, GAD65 + more 

Drs. Chaichian and Dall'Era explore the “treat to target” approach in lupus, including key targets like DORIS remission and lupus low disease activity state.

This conversation is with men's fertility expert Josh Paigen — whose path took him from a childhood fascination with the natural world to helping men and couples prepare for healthy conception. We explore the alarming global decline in sperm count, why preconception health is about far more than simply being able to conceive, and Josh's five pillars of male fertility: sustenance, purity, exercise, rest, and mindset. Along the way, we dive into the roles of nutrition, environmental toxins, circadian rhythms, and even inherited trauma in shaping reproductive health — and how small, intentional lifestyle shifts can have a profound impact on future generations.You can expect to learn• Why sperm count is plummeting (and why this matters)• Five pillars of male fertility you can start today• How diet, toxins, and lifestyle shape reproductive health• Sleep, stress, and mindsets' hidden role in fertility• Epigenetics: how trauma and health choices get passed on• Simple changes that can boost fertility and overall vitality[Timestamps]05:43 Understanding Preconception Health11:54 Sperm as a Biomarker for Health17:27 Nutrition and Sperm Health23:50 Understanding Everyday Toxins29:22 Minimizing EMF Exposure38:19 Circadian Rhythms and Hormonal Balance47:56 Mindset and Holistic Health55:35 The Interconnection of Health and Fertility01:00:58 Understanding Epigenetics and Trauma01:08:36 Challenging Myths in FertilityConnect with Josh

In today's episode, we had the pleasure of speaking with Balazs Halmos, MD, MS, about the phase 2 VISION trial (NCT02864992) evaluating tepotinib (Tepmetko) in patients with MET exon 14 skipping mutation–positive non–small cell lung cancer (NSCLC). Dr Halmos is a professor in the Department of Oncology (Medical Oncology) and the Department of Medicine (Oncology and Hematology), director of Thoracic Oncology, and associate director of Clinical Science at Montefiore Einstein Comprehensive Cancer Center in Bronx, New York. In our exclusive interview, Halmos discussed the rationale and design of the VISION trial, the significance of MET exon 14 skipping mutations as a distinct oncogenic driver, and the clinical utility of tepotinib, which is a selective MET TKI. He reviewed the trial's efficacy results, which demonstrated consistent response rates across lines of therapy and diagnostic methods, as well as tolerability findings that highlighted the importance of monitoring and managing MET-related adverse effects. Dr Halmos also reflected on subgroup analyses from the trial, noting the agent's activity across treatment settings, particularly in older patients and those with central nervous system involvement. Additionally, Halmos underscored the critical role of comprehensive biomarker testing in NSCLC, highlighting how parallel tissue- and circulating tumor DNA–based testing can optimize timely identification of actionable alterations and ensure patients receive the most effective frontline therapy. He also discussed practical considerations for dose selection and modifications with tepotinib, offering insights into strategies for maximizing treatment benefit and maintaining patient quality of life.

Eine individualisierte Diagnose ermöglicht Krebspatient:innen eine effektive und schonende Therapie. Doch obwohl die Biotech-Forschung in den letzten Jahren immer wieder große Durchbrüche erzielt hat, kommt davon im Kliniklabor oft nur wenig an - oder viel zu spät. Unsere heutige Gesprächspartnerin, Molekularbiologin und Unternehmerin Dr. Christina Port, hat sich am Anfang ihrer Gründungsreise die Frage gestellt, wie sie diese Lücke zwischen Forschung und klinischer Anwendung schließen kann. Mit ihrem Startup 2NA FISH entwickelte sie eine Plattform, die RNA-Veränderungen im räumlichen Gewebekontext sichtbar macht und so eine differenzierte Diagnose und Behandlung ermöglicht. In der Forschung ist der Ansatz bereits seit Jahren etabliert – doch fehlte es bisher an Verfahren, die ohne teure Spezialgeräte auskommen. Mit KI-unterstützer DNA-Nanotechnologie macht 2NA FISH die Cutting-Edge-Methode jetzt auch für Kliniken erschwinglich. Für diesen Ansatz wurde das Startup bereits mehrfach prämiert, unter anderem mit dem Gründungspreis des Bundeswirtschaftsministeriums. In dieser Podcast-Folge erfahrt ihr, wie aus jahrelanger Laborarbeit ein marktreifes Produkt erwachsen ist und warum die Gründerin auf klare Workflows und frühe Nutzerintegration setzt. Port berichtet von ihrer Entscheidung, auf eine akademische Karriere zu verzichten, und wie sie es geschafft hat, mit Unsicherheit umzugehen. Wir sprechen auch über praktischen Themen der Unternehmensgründung: Funding, Förderprogramme und die Frage, wie man ein Team nicht nur richtig stafft und führt, sondern auch bei Laune hält. Wer wissen will, wie Deep Tech mit ganz viel Expertise, Mut und einer Prise Zufall in echten Patientennutzen übersetzt wird, sollte unbedingt reinhören. Unsere neue Folge bietet eine spannende Mischung aus wissenschaftlicher Tiefe und authentischer -Gründerinnen-Erfahrung.

Dr. Ben Thompson joins Longevity Junkie to expose the silent link between hearing loss and dementia. From noise exposure to sound therapy, this episode breaks the myths and lays out proven strategies. This deep dive explains what really works for treatment and prevention.Get started with Treble Health:Schedule a complimentary telehealth consultation: treble.health/free-telehealth-consultation Take the tinnitus quiz: https://treble.health/tinnitus-quiz-1Download the Ultimate Tinnitus Guide: 2024 Edition: https://treble.health/tinnitus-guide-2024

Klinisch Relevant ist Dein Wissenspartner für das Gesundheitswesen. Drei mal pro Woche, nämlich dienstags, donnerstags und samstags, versorgen wir Dich mit unserem Podcast und liefern Dir Fachwissen für Deine klinische Praxis. Weitere Infos findest Du unter https://klinisch-relevant.de

Timestamps:6:00 - Tackling the early detection of sepsis 17:17 - Why obsess over hard challenges?27:41 - Marketing a new biomarker 34:20 - Expanding and delegating to distributors  This episode was co-produced with Innovaud, the innovation and investment promotion agency for the canton of Vaud.About Patrick Pestalozzi & François Capel:Patrick Pestalozzi is a former management consultant and Silicon Valley executive with 3 decades of global experience, most recently as the Vice-President of Global Strategic Accounts for Mindmaze and as the CEO at GaitUp, a Mindmaze subsidiary. In 2024 he became the CEO at Abionic, a medtech EPFL spin-off founded back in 2010.François Capel is an Innovation Director with 10+ years of experience driving innovation within fast-paced environments and innovation-driven industries. He is currently a full-time advisor at Innovaud, the innovation and investment promotion agency for the canton of Vaud.During his chat with Merle and François, Patrick shared his experience as Abionic CEO. Abionic is on a mission to transform sepsis diagnoses through the use of nanofluids, and their flagship product, abioSCOPE®, a near-patient rapid diagnostic platform, delivers lab-quality results from a drop of blood within minutes, providing valuable clinical insights and actionable information at the point-of-care.Don't forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠ TikTok⁠⁠⁠⁠⁠⁠⁠⁠, and⁠⁠⁠⁠⁠⁠⁠⁠ Youtube ⁠⁠⁠⁠⁠⁠⁠⁠so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly giveaways or founders' dinners.

Host: Brian P. McDonough, MD, FAAFP Guest: Marie Wood, MD Traditional cancer screening has always focused on individual organs, but now, multi-cancer early detection (MCED) tests are changing that paradigm. By analyzing multiple biomarkers through a single blood draw, MCED testing can detect signals from a variety of cancers—many of which currently lack effective screening tools. These multi-biomarker approaches not only outperform single-marker tests, but also demonstrate scientific rigor and clinical utility. Still, challenges remain, including false positives and integration with standard screening protocols. Joining Dr. Brian McDonough to explore the rationale for using a multi-biomarker approach to MCED testing is Dr. Marie Wood, Professor of Medicine at the University of Colorado School of Medicine and Medical Director of the Hereditary Cancer Program at the CU Cancer Center.

Welches Organ ist meine Schwachstelle? Wie jung ist mein Körper? Wie können wir gesund alt werden? Das biologische Alter beschäftigt uns je länger, je mehr. Genau da setzt der Schweizer Forscher Tony Wyss Coray an. Er kann mit einem neuen Verfahren das Alter der einzelnen Organe feststellen. Der Bluttest Als erste Person in der Schweiz macht Tobias Müller einen Test, welcher das Alter seiner Organe bestimmt. Dabei wird untersucht, welche organspezifischen Proteine im Blut aktiv sind und welche Konzentration sie aufweisen. Ist ein Organ älter als das chronologische Alter besteht ein erhöhtes Erkrankungsrisiko für das entsprechende Organ. Studien haben gezeigt, dass jeder fünfte Mensch über 50 Jahre mindestens ein Organ hat, das signifikant über dem chronologischen Alter liegt. Erste Studien Den Test hat der Forscher Tony Wyss-Coray entwickelt. Der Schweizer forscht und lehrt an der Eliteuniversität Stanford in den USA. Ursprung seiner Forschung war ein Experiment mit Mäusen, das in der Schweiz nicht genehmigt wurde. Dabei wurden eine junge und eine alte Maus aneinandergenäht. Das junge Blut hat die Organe der älteren Maus verjüngt und umgekehrt. Biomarker im Blut Heute kennen Tony Wyss-Coray und seine Kolleginnen Tausende Proteine, die sie einem spezifischen Organ zuweisen können. Aufgrund der Zusammensetzung des Blutes können die Forschenden das Alter jedes Organs schätzen. Wenn die Mediziner sehen, dass ein Organ schneller altert, ist das eine Zusatzinformation, die bislang in der Medizin noch nicht zur Verfügung steht. So kann man genauer und tiefer hinschauen und dann die Empfehlungen so gestalten, dass man frühzeitig reagieren kann, bevor sich strukturelle Veränderungen einstellen. Neuer Campus in Basel In Basel eröffnen Tony Wyss-Coray und die Chefärztin und Heike A. Bischoff-Ferrari einen Campus für eine gesunde Langlebigkeit im Felix-Platter-Spital. Dort sollen Menschen überprüfbare und bestätigte Daten zu ihrem Alter erhalten. Parallel wird auch die Forschung für eine gesunde Altersmedizin vorangetrieben.

Welches Organ ist meine Schwachstelle? Wie jung ist mein Körper? Wie können wir gesund alt werden? Das biologische Alter beschäftigt uns je länger, je mehr. Genau da setzt der Schweizer Forscher Tony Wyss Coray an. Er kann mit einem neuen Verfahren das Alter der einzelnen Organe feststellen. Der Bluttest Als erste Person in der Schweiz macht Tobias Müller einen Test, welcher das Alter seiner Organe bestimmt. Dabei wird untersucht, welche organspezifischen Proteine im Blut aktiv sind und welche Konzentration sie aufweisen. Ist ein Organ älter als das chronologische Alter besteht ein erhöhtes Erkrankungsrisiko für das entsprechende Organ. Studien haben gezeigt, dass jeder fünfte Mensch über 50 Jahre mindestens ein Organ hat, das signifikant über dem chronologischen Alter liegt. Erste Studien Den Test hat der Forscher Tony Wyss-Coray entwickelt. Der Schweizer forscht und lehrt an der Eliteuniversität Stanford in den USA. Ursprung seiner Forschung war ein Experiment mit Mäusen, das in der Schweiz nicht genehmigt wurde. Dabei wurden eine junge und eine alte Maus aneinandergenäht. Das junge Blut hat die Organe der älteren Maus verjüngt und umgekehrt. Biomarker im Blut Heute kennen Tony Wyss-Coray und seine Kolleginnen Tausende Proteine, die sie einem spezifischen Organ zuweisen können. Aufgrund der Zusammensetzung des Blutes können die Forschenden das Alter jedes Organs schätzen. Wenn die Mediziner sehen, dass ein Organ schneller altert, ist das eine Zusatzinformation, die bislang in der Medizin noch nicht zur Verfügung steht. So kann man genauer und tiefer hinschauen und dann die Empfehlungen so gestalten, dass man frühzeitig reagieren kann, bevor sich strukturelle Veränderungen einstellen. Neuer Campus in Basel In Basel eröffnen Tony Wyss-Coray und die Chefärztin und Heike A. Bischoff-Ferrari einen Campus für eine gesunde Langlebigkeit im Felix-Platter-Spital. Dort sollen Menschen überprüfbare und bestätigte Daten zu ihrem Alter erhalten. Parallel wird auch die Forschung für eine gesunde Altersmedizin vorangetrieben.

Can stress actually improve flower quality? In this episode, I sit down with Dr. José Leme to dive into the science of plant stimuli and how growers can apply it in practice. We cover:

Featuring an interview with Dr Shannon N Westin, including the following topics: Biomarker testing and utility in ovarian cancer (OC) (0:00) Selection of a PARP inhibitor for the treatment of OC (9:18) Addition of immunotherapy to up-front treatment of OC (15:50) Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10) Selection of treatment for recurrent OC (21:46) Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22) Adjuvant therapy for EC (32:28) Utility of lenvatinib/pembrolizumab in EC (35:08) Clinical findings supporting the potential use of selinexor for EC (39:42) Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22) Management of adverse effects associated with T-DXd (49:49) CME information and select publications

How confident are you navigating biomarker conversations with your gastric cancer patients? Credit available for this activity expires: 8/19/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002840?ecd=bdc_podcast_libsyn_mscpedu

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Fabien Maldonado, MD, FCCP Guest: Adam H. Fox, MD, MSc Cutting-edge biopsy methods and streamlined biomarker testing are transforming early-stage non-small cell lung cancer (NSCLC) care. Hear from Drs. Gerard Silvestri, Fabien Maldonado, and Adam Fox as they discuss the evolution of bronchoscopic techniques, insights from landmark trials, and the role of pragmatic clinical research in refining biopsy approaches. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Maldonado is a Professor of Medicine and Thoracic Surgery, the Pierre Massion Director in Lung Cancer Research, and the Director of Interventional Pulmonology Research at Vanderbilt University; and Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Die Folge auf YouTube ansehen: https://youtu.be/u6xKNd3xB7U...und YouTube Kanal gleich abonnieren und keine neue Folge mehr verpassen.ZusammenfassungIn dieser spannenden Episode tauchen wir tief in die Welt der GLP-1-Agonisten ein, besser bekannt als Abnehmspritze (Markennamen wie Ozempic und Wegovy).

Guest: Mateo Mejia Saldarriaga, M.D. Mateo Mejia Saldarriaga, M.D., a hematologist/oncologist at NewYork-Presbyterian and Weill Cornell Medicine, explains how he and his team conducted a retrospective study that identified a biomarker to enhance treatment planning for BCMA CAR T-cell therapy in multiple myeloma. By measuring absolute lymphocyte count (ALC) through a routine CBC 15 days after a CAR T-cell therapy injection, they found patients with an ALC > 1,000 had a median progression-free survival (PFS) of 30 months whereas patients with an ALC ≤ 500 had a median PFS of 6 months. This new biomarker is now being leveraged to help doctors predict whether a patient is benefiting from treatment in as early as 15 days. © 2025 NewYork-Presbyterian

Guest: Brian Slomovitz, MD Our treatment approach for patients with endometrial cancer is evolving, with antibody-drug conjugates (ADCs) and biomarker-driven therapies showing promise. Dr. Brian Slomovitz highlights future directions that could redefine treatment pathways for patients with advanced or recurrent disease. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Guest: Brian Slomovitz, MD Our treatment approach for patients with endometrial cancer is evolving, with antibody-drug conjugates (ADCs) and biomarker-driven therapies showing promise. Dr. Brian Slomovitz highlights future directions that could redefine treatment pathways for patients with advanced or recurrent disease. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

In a discussion with CancerNetwork®, Jacob Sands, MD, assistant professor of Medicine at Harvard Medical School, thoracic oncologist at the Dana-Farber Cancer Institute, and investigator of the phase 2 TROPION-Lung05 trial (NCT04484142) and phase 3 TROPION-Lung01 trial (NCT04656652), which supported the accelerated approval of datopotamab deruxtecan-dlnk (dato-DXd; Datroway) in pretreated EGFR-mutant metastatic NSCLC in June 2025, discussed safety and efficacy considerations for the agent's use.1-3 He began by outlining a combined cohort of the TROPION-Lung05 and TROPION-Lung01 trials, which collectively showed an efficacy benefit with dato-DXd in patients with EGFR-mutant disease vs docetaxel. In the combined cohort, the median progression-free survival with dato-DXd reached 5.8 months, and the median overall survival was 15.6 months. Additional efficacy data revealed an objective response rate of 45% (95% CI, 35%-54%) and a median duration of response of 6.5 months (95% CI, 4.2-8.4).  Furthermore, Sands highlighted the most common toxicities observed with dato-DXd in this population, which included stomatitis, interstitial lung disease (ILD), and ocular toxicities. He also reviewed management strategies to mitigate their incidence and severity. Specifically, remedies include prophylaxis, oral hygiene, and dose reductions for stomatitis; using preservative-free eye drops and ophthalmology visits for ocular toxicity management and prevention; and monitoring for any incidence of high-grade ILD. He then touched upon next steps for research in this disease state, including the phase 2 ORCHARD trial (NCT03944772) evaluating dato-DXd with osimertinib (Tagrisso) in the second-line setting after progression on osimertinib and the phase 3 TROPION-Lung15 trial (NCT06417814), which is evaluating chemotherapy vs dato-DXd alone or with osimertinib.4,5 Sands concluded by discussing the implications for toxicity management in patients who experience responses that exceed median outcomes, suggesting that the toxicity profile may be more severe for this group. Emphasizing the broadness of outcomes with any drug, he expressed that patients with experiences that deviate from the observed median outcome are an important consideration for clinical practice. References Sands J, Ahn MJ, Lisberg A, et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study. J Clin Oncol. Published online January 6, 2025. doi:10.1200/JCO-24-01349 Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol. Published online September 9, 2024. doi:10.1200/JCO-24-01544  FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer. News release. FDA. June 23, 2025. Accessed July 29, 2025. https://tinyurl.com/mtay7ab9 Yu HA, Goldberg SB, Le X, et al. Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD). Clin Lung Cancer. 2021;22(6):601-606. doi:10.1016/j.cllc.2021.06.006 A study to investigate the efficacy and safety of dato-DXd with or without osimertinib compared with platinum based doublet chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (TROPION-Lung15). ClinicalTrials.gov. Updated July 16, 2025. Accessed July 29, 2025. https://tinyurl.com/56z3dmsp

This episode originally dropped on February 12, 2025.Bill Campbell, PhD, has spent his entire career as a fat loss researcher. So when his wife hit menopause and wanted help with body composition changes, he thought it would be easy. Spoiler alert: It was not. Which made him realize his field had a lot to learn, especially about active women whose bodies change even when their training and nutrition has not. Now he's on a mission, diving into the literature and conducting research of his own to further our understanding of body composition changes during this time of life. We talk all about it, what he's learned, and his work developing a Female Fitness Menopause Survey to learn more.Bill Campbell, PhD is a Professor of Exercise Science and Director of the Performance and Physique Enhancement Laboratory at the University of South Florida. He is also a Certified Strength & Conditioning Specialist from the National Strength & Conditioning Association and former president of the International Society of Sports Nutrition (where he is also 1 of 35 individuals to be recognized as a ‘Fellow' of the organization—an honor reserved for those individuals who have outstanding contributions to the field of sports nutrition). He has published over 200 scientific papers and abstracts, three textbooks, and 20 book chapters in areas related to physique enhancement, sports nutrition, resistance training, and dietary supplementation. You can learn more about him and his work at www.billcampbellphd.comResourcesEstrogen modulates metabolic risk profile after resistance training in early postmenopausal women: a randomized controlled trial, hereTransdermal Estrogen Therapy Improves Gains in Skeletal Muscle Mass After 12 Weeks of Resistance Training in Early Postmenopausal Women, hereMetabolic effects of menopause: a cross-sectional characterization of body composition and exercise metabolism, herePowerpenia Should be Considered a Biomarker of Healthy Aging, herePurchase the Menopause Course Bundle and Save $111! https://learning.feisty.co/ Sign up for our FREE Feisty 40+ newsletter: https://feistymedia.ac-page.com/feisty-40-sign-up-page Follow Us on Instagram:Feisty Menopause: @feistymenopause Hit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099 Support our Partners:Hettas: Use code FEISTY20 for 20% off at https://hettas.com/ Midi Health: You Deserve to Feel Great. Book your virtual visit today at https://www.joinmidi.com/ Previnex: Get 15% off your first order with code HITPLAY at https://www.previnex.com/ This podcast uses the following third-party services for analysis: Spotify Ad Analytics - https://www.spotify.com/us/legal/ad-analytics-privacy-policy/Podcorn - https://podcorn.com/privacyPodscribe - https://podscribe.com/privacy

In this podcast we share a few selected highlights from the Alzheimer's Association International Conference (AAIC) pre-conference and first day of the main event in Toronto and Online, 27the - 31st July. -- Dr Tamlyn Watermeyer hosts the show with special guests: Dr Emily Ho, Assistant Professor at Northwestern University Dr Laura Stankeviciute, Postdoctoral Researcher & Scientific Project Manager at University of Gothenburg Joseph Russell, NIHR Research Assistant at Northumbria University -- The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Main plenary talk from the day came from Sylvia Villeneuve, Ph.D. Associate Professor, Department of Psychiatry — McGill University, Canada talk about Biomarker and Clinical Trajectories of Preclinical AD. -- #AAIC25 @alzassociation -- Find more information on our guests, and a full transcript of this podcast on our website at: https://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

“Next-generation sequencing, or NGS, can be used to help us determine if the patient has specific biomarkers we can identify and use to target for treatment. Certain findings can tell us if a particular treatment might work for that patient, and we can see if there are any genetic variants we might have a biomarker targeted agent to use to treat them with,” ONS member Jackie Peterson, MSN, RN, OCN®, NE-BC, MBA, ambulatory nurse manager at the University of Chicago Medical Center in Illinois, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about prostate cancer and biomarker testing.  This podcast is sponsored by AstraZeneca and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod    Licensed under Creative Commons by Attribution 3.0   Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 180: Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Disorders Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Germline and Somatic Variants: What Is the Difference? Help Patients Understand Genomic Variants of Unknown Significance Prostate Cancer Clinical Trials Don't Reflect Racial Diversity—And It's Getting Worse Over Time Prostate Cancer Disparities Disappear With Equal Access to Care Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations The Case of the Genomics-Guided Care for Prostate Cancer ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing articles: Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management Prostate Cancer: How Nurse Practicioners Can Aid in Disease Diagnosis and Management Oncology Nursing Forum article: Identification of Symptom Profiles in Prostate Cancer Survivors Other ONS Resources: Biomarker Database (refine by prostate cancer or specific biomarkers) Clinical tool/case study: Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Genomics and Precision Oncology Learning Library Huddle Card: Genomic Biomarkers Infographic: Talking to Your Patient About a Germline Variant of Uncertain Significance (VUS) American Cancer Society - Genetic Testing and Counseling for Prostate Cancer Risk American Cancer Society - Prostate Cancer Clinicaltrials.gov National Cancer Institute - Prostate Cancer National Comprehensive Cancer Network ZERO Prostate Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode “Some of the risk factors for developing prostate cancer include age, race, family history, and certain genetic changes or variants. Prostate cancer has some hereditary components, but most prostate cancer occurs in men without any significant family history of it.” TS 1:31 “Key biomarkers include PSA and prostate cancer gene 3, which is PCA3, and prostate-specific membrane antigen, or PSMA. Other biomarkers that are important for us to test include BRCA1, BRCA2, and Lynch syndrome–associated genes, which are MLH1, MSH2, MSH6, PMS2, and EPCAM. Biomarkers can be collected via your blood, urine, saliva, or tissue samples, so these are different ways that we can test and look for biomarkers in our patients.” TS 3:24 “It does matter how advanced the disease is. Usually, for our castrate-sensitive patients, they respond better to androgen deprivation therapy because that really is slowing down the growth of the cancer by reducing the available testosterone that the cancer needs to grow. Whereas our patients that are more advanced and have castrate-resistant prostate cancer, that cancer will continue to grow despite having the lowered testosterone levels, so they might need additional layers of treatment to really get their cancer under control.” TS 7:50 “When I talk to [patients] about biomarker testing, I tell them it's another tool in our toolbox that we can use to help us determine if they might benefit from other therapy options now or in the future. I tell them that sometimes we'll get a report back with a variant of unknown significance, and basically that means that we don't really know whether or not this has an impact on their health or risk factors for the disease. That can sometimes be a little bit of a concern for these patients, so we just have to reassure them that we're continually doing research around biomarker testing. The science is always advancing, so if there's something that [researchers] find in the future, we'll make them aware of that.” TS 9:08 “One of the biggest topics I think about is the inequity that exists in biomarker testing and research, especially surrounding the African American population. When these tests were developed, that population really wasn't studied as much, so there's not a lot of good data yet to make a decision or impact on those patients and that population.” TS: 12:30

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Baseline Cardiac Biomarker Levels as Predictors of Cancer Risk in the MESA Cohort.

Mauro Stara is the founder of Six Pack CEO and a peak-performance strategist for time-pressed leaders. Drawing on his background in banking and a science‑driven approach that starts with deep biomarker analysis, Mauro helps CEOs resolve hidden hormonal roadblocks, build cover‑model physiques, and unlock the energy they need to scale their companies without sacrificing health or family life.   https://www.linkedin.com/in/mauro-stara-4b4295217/ https://www.instagram.com/maurostaraofficial/   This podcast is brought to you by LMNT Electrolytes! It's great for a hot summer day, a workout, or just working at your desk with cold water. Check it out and get your free sample pack along with any regular purchase when you use my custom link, www.drinklmnt.com/ScottMys. The LMNT Sample Pack includes one packet of their most popular flavors. This is the perfect offer for 1) anyone who is interested in trying all of our flavors or 2) anyone who wants to introduce a friend to LMNT. Go to www.drinklmnt.com/ScottMys to claim this awesome deal!   Interested in working with me 1-1? I offer personalized coaching where I can help you reach your goals whether it be fat loss, muscle building, health improvements, or all of the above. I provide tailored nutrition, training, and supplementation advice (one or all together) with 24/7 ongoing support to help guide you every step of the way. DM me on Instagram and I can answer any questions. If you like, we can even set up a FREE consult call to go over your goals, answer questions, and discuss what it could look like to work together!

Howie and Harlan are joined by Azita Emami, dean of the Yale School of Nursing, to discuss the school's approach to training nurses who can have a seat at the table of healthcare decision-making. Harlan reports on his new study showing the low levels of evidence required for medical devices in the FDA's Breakthrough Devices Program; Howie provides some good news about infectious diseases including malaria and HIV. Links: Breakthrough devices? Harlan Krumholz: “FDA Authorization of Therapeutic Devices Under the Breakthrough Devices Program” FDA: Breakthrough Devices Program “Many medical devices deemed ‘breakthrough' by FDA are backed by patchy evidence” FDA Facts: Biomarkers and Surrogate Endpoints Harlan Krumholz: “Class I Recalls of Cardiovascular Devices Between 2013 and 2022 : A Cross-Sectional Analysis” Azita Emami “Americans' Ratings of U.S. Professions Stay Historically Low” “University of Washington selects Azita Emami as dean of School of Nursing” “Azita Emami named new dean of School of Nursing” “The Report of the Rockefeller Foundation on Nursing Education: A Review and Critique” Cleveland Clinic: DHEAS Test “DHEA as a Biomarker of Stress: A Systematic Review and Meta-Analysis” Azita Emami: “Assessing stress using repeated saliva concentration of steroid hormones in dementia care dyads: results from a controlled pilot care music intervention” Azita Emami: “The Feasibility and Acceptability of In-Home Saliva Collection for Stress in Persons With Dementia and Their Family Caregivers” Infectious diseases Mayo Clinic: Malaria WHO: World Malaria Report 2024 “Georgia certified malaria-free by WHO” “Suriname certified malaria-free by WHO” The Global Fund to Fight AIDS, Tuberculosis and Malaria “Novartis wins approval for first malaria drug for newborns and babies” “FDA Approves a Twice-Yearly Shot to Prevent HIV” “U.S. measles cases hit highest level in 33 years, CDC reports” Texas Department of State Health Services: Measles Outbreak “The West Texas measles outbreak has started to slow for the first time since January” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

BUFFALO, NY - July 7, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience.” In this study, a research team led by first author Fei Fei and corresponding author Michelle Afkhami from the City of Hope Comprehensive Cancer Center investigated a rare and aggressive type of blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN). Their research uncovered frequent mutations in key genes and identified CCDC50 as a potential biomarker for diagnosis and disease monitoring. These findings could help improve how this cancer is detected and treated in the future. BPDCN most often affects older adults and is known for its rapid progression and poor survival rates. The researchers performed genetic sequencing on 21 patients to better understand the disease. They found that two genes, TET2 and ASXL1, were frequently mutated in these patients and were linked to worse survival, especially in those over 65 years old. “Our study revealed that TET2 (57%) and ASXL1 (33%) were the most frequently mutated genes, followed by NRAS (29%), SRSF2 (14%), ZRSR2 (14%), and KMT2D (14%).” The study also discovered that a gene called CCDC50 was expressed at much higher levels in BPDCN samples compared to other blood cancers, such as acute myeloid leukemia and chronic monomyelocytic leukemia. This suggests that CCDC50 may help clinicians distinguish BPDCN from other similar diseases. Importantly, CCDC50 levels dropped significantly in patients whose disease went into remission, highlighting its potential as a tool for tracking disease activity over time. Researchers further observed that patients who received stem cell transplants lived longer than those who did not, reinforcing the importance of this treatment approach. However, BPDCN remains a challenging disease with an overall poor outlook, making these findings an important step toward better care. This research provides new insights into the genetic changes behind BPDCN and points to CCDC50 as a promising marker to improve diagnosis and monitor treatment success. Larger studies will be needed to confirm these results and bring these discoveries closer to use in routine medical practice. DOI - https://doi.org/10.18632/oncotarget.28742 Correspondence to - Michelle Afkhami - mafkhami@coh.org Video short - https://www.youtube.com/watch?v=wUjr3uU3onI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28742 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Next-generation sequencing (NGS), CCDC50 To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

In this episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Midhun Malla, MD, of the University of Alabama at Birmingham, to discuss therapeutic options for patients with metastatic colorectal cancer (mCRC), particularly in the third-line setting and beyond. In the final part of this 3-part episode miniseries, Drs Park and Malla explored the challenges faced by community oncologists, especially in rural or underserved areas, in accessing clinical trials, which remain a preferred disease management approach due to their role in advancing novel therapies. However, in the absence of trial availability or when patients are ineligible, they emphasized the importance of evidence-based, FDA-approved agents for later lines of therapy. Three primary agents were discussed for patients who have progressed on first-line FOLFOX (folinic acid, fluorouracil, and oxaliplatin) and second-line FOLFIRI (folinic acid, fluorouracil, and irinotecan) regimens: trifluridine/tipiracil (TAS-102; Lonsurf) plus bevacizumab (Avastin); fruquintinib (Fruzaqla); and regorafenib (Stivarga). These agents offer viable treatment pathways in biomarker-unselected patient populations. However, direct comparisons between these agents are lacking, as most were tested against placebo controls. The choice among them is often individualized based on patient performance status, prior exposure to biologics, and toxicity profiles. TAS-102 plus bevacizumab has generated promising results, though real-world data may show diminished efficacy due to frequent prior exposure to 5-fluorouracil and bevacizumab in US patients. Fruquintinib offers a VEGF-targeted approach with a more favorable hematologic toxicity profile, whereas regorafenib is associated with notable adverse effects, including hypertension, gastrointestinal toxicity, and mucositis. Park and Malla emphasized the importance of treatment sequencing, toxicity management, and individualized patient-centered care, including consideration of dose modifications to preserve quality of life in later-line settings. In addition to later-line options, the conversation also touched on emerging frontline therapies. Notable investigational agents include zanidatimab-hrii (Ziihera) and KRAS G12C–directed therapies. Additionally, a novel integrin-targeted cytotoxin is currently under evaluation at the University of Alabama at Birmingham in patients with treatment-naive mCRC. This agent induces apoptosis via caspase-8 activation and has demonstrated encouraging preclinical activity. Overall, the discussion highlighted a nuanced, biomarker-informed, and patient-tailored approach to mCRC management, emphasizing both the value of clinical trials and the importance of optimizing currently available therapies.

Send us a textIn this episode of the WTR Small-Cap | Biotech Spotlight Crossover, Water Tower Research's Tim Gerdeman is joined by Dr. Chris Witowski, CEO of Psilera, and WTR Senior Analyst Robert Sassoon for an insightful discussion on the company's pioneering work in neuroplastogen drug development and delivery technologies.Dr. Chris  Witowski, CEO and Co-Founder of Psilera, an early-stage biotech company focused on developing next-generation neuroplastegens for neurological and neuropsychiatric disorders, shares his thoughts and insights on the evolution of biomarkers in the neurosciences, the latest developments and trends in CNS-focused biomarkers and the potentially transformative impact they will have on the CNS treatment landscape.Tune in to learn more about Psilera's vision for the future of neurotherapeutics and how the company is working to transform the treatment landscape for CNS disorders.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on A New Biomarker of Aging Derived From Electrocardiograms Improves Risk Prediction of Incident Cardiovascular Disease.

Please visit answersincme.com/ZDE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses best practices for implementing biomarker testing in non-small cell lung cancer (NSCLC) management. Upon completion of this activity, participants should be better able to: Apply current guideline recommendations for biomarker testing to the management of patients with NSCLC, Outline practical strategies within the multidisciplinary team to optimize biomarker testing for patients with NSCLC; and Discuss methods to link biomarker testing to treatment decision-making for patients with NSCLC.

Tired of overpriced marketing tools? Omnisend gives you pro-level automation without draining your wallet. Try it here and see why I made the switch: https://your.omnisend.com/codiesanchez30 Codie and Dr. Rena Malik discuss the complexities of female orgasm, the myths surrounding male sexual performance, and the dynamics of libido in relationships. They delve into the complexities of sexual education, the impact of pornography on young people's understanding of sex, and the importance of open communication between parents and children. The discussion also touches on the future of intimacy in the age of AI and the importance of maintaining human connection. Chapters 00:00 Intro 12:49 The Myths of Male Sexual Performance 26:02 Navigating Libido and Sexual Desire in Relationships 31:17 The Impact of Porn on Sexual Education 35:04 Navigating Conversations About Sex with Kids 39:53 Exploring Personal Sexuality and Preferences 42:55 Sex as a Biomarker of Overall Health 45:51 The Changing Landscape of Sexual Relationships 48:32 Understanding the Pelvic Floor 53:37 The Role of Substances in Sexual Experience 01:00:04 The Future of Intimacy and AI MORE FROM BIGDEAL:

This episode features Prof. Dr. Robert Perneczky who serves as Professor of Translational Dementia Research and Head of Geriatric Psychiatry at Ludwig-Maximilians University in Munich. Dive into the intricate realm of dementia and neurocognitive disorders as he reveals groundbreaking advancements in disease-modifying treatments and emphasizes the crucial role of lifestyle factors in mitigating dementia risk. Explore how cutting-edge innovations in biomarkers and interdisciplinary methodologies are revolutionizing the future of dementia care and gain insightful strategies to enhance resilience against neurodegeneration.

Sie brachten 1925 ein wenig Ordnung in die chaotische Welt der Quanten – allen voran Werner Heisenberg. Ausserdem: Wo steht der Hype um Taurin als Wundermittel gegen das Altern heute? Und: Wir schauen nochmals genau hin, was kam im Lötschental runter, was liegt nun da und was bedeutet das jetzt? (00:00) Schlagzeilen (00:45) Die Geburtsstunde der Quantenmechanik: Vor 100 Jahren brachte der 23-jährige Werner Heisenberg die Quantenmechanik auf der Insel Helgoland aufs Papier. Dorthin war er vor den Pollen gelüchtet. Er lüftet Nase und andere Schleimhäute und offenbar auch seinen Kopf. (07:22) Meldungen: Das ungewisse Schicksal der Wissenschaft in den USA; der Schutz der Nashörner in Südafrika (12:36) Gehyptes Taurin: Vor zwei Jahren wurde Taurin in der Fachzeitschrift Science als Wundermolekül gehypt: Die in zahlreiche biologische Prozesse involvierte Aminosäure verlangsame den Alterungsprozess. Eine neue Science-Studie kommt nun zum gegenteiligen Schluss – Taurin eigne sich nicht als Biomarker fürs Altern. Ein Lehrstück über ein Forschungsfeld, das auch von kommerziellen Interessen getrieben ist. (19:06) Unverrückbare Schutthalde: Beim Bergsturz von Blatten donnerte keine Fels- und Schuttlawine ins Tal, sondern ein Gletscher mit Geröll obendrauf. Dies machte diesen Bergsturz so zerstörerisch und ist mit ein Grund, warum sich der mächtige Schuttkegel über dem Dorf nicht so einfach wegräumen lässt. Welche Rolle spielen Gletscher bei Bergstürzen und wie spielt dabei der Klimawandel mit? Links: Sachbuch: Thomas de Padova, Quantenlicht. Das Jahrzehnt der Physik 1919-1929 hanser-literaturverlage.de/personen/thomas-de-padova-p-1343 Enthornte Nashörner : science.org/doi/10.1126/science.ado7490 Taurin-Studie: science.org/doi/10.1126/science.adl2116

Let's be honest, perimenopause and menopause are incredibly transformative journeys that NONE of us asked for. So, it's up to us to find meaning and purpose amid these shifts.  That's what this episode is all about– finding the power you hold to understand what's really happening in your body at this stage of life.  It's time to decode the symptoms you've been told to brush off again and again by your doctor, and take ACTION that changes your health trajectory today, and for all your days to come. In this episode, I'll provide you with the framework for understanding your body in perimenopause and help you take actionable steps to feel more alive and achieve the results you deserve. We're diving into labs, biomarkers, and how to harness this data to become the ultimate CEO of your health, feeling more confident in your body every day. Tune in here and discover how to reclaim your story and feel empowered every step of the way!  IN THIS EPISODE Why your metabolic health is key to your overall wellness  The 5 biomarkers of optimal metabolic health  Navigating the massive knowledge gap in our healthcare system How to avoid chronic complications down the road  The three truths you need to know about your metabolic health  Understanding your specific lab ranges and analyzing your results  Action steps to find out if you're metabolically healthy  QUOTES “88% of women over 45 years old will have some level of metabolic dysfunction, and insulin resistance is really the silent force behind 8 out of the 10 top causes of death in the US.”  “Metabolic dysfunction and syndrome occur when three or more of the following biomarkers are out of range.” “What a lot of us don't realize is the things that are manifesting in our sixties and seventies really started in our forties. And often they could have been avoided with earlier, more targeted interventions.” RESOURCES MENTIONED The Perimenopause Revolution by Dr. Mariza Snyder: Pre-order your copy here and get IMMEDIATE ACCESS to bonuses like The Perimenopause Power Toolkit, workout videos, recipes & more!  www.qualialife.com/drmariza, Coupon Code: ENERGIZED BEAM Minerals: Use code ENERGIZED at checkout for 20% off your first order! RELATED EPISODES  #648: This Changes Everything: The Perimenopause Revolution Every Woman Needs Now 595: How to Master Your Metabolism and Reverse Cellular Aging in Midlife + My Best Tips to Thrive with Dr. Mariza 584: The Health Costs of Our Modern Life & How to Start Feeling Better with Dr. Casey Means #541: Why Functional Labs Are a Game Changer for Your Health with Dr. Kela Smith

Levels offers biomarker testing to give you more insight into your health status so you can understand the root causes of your symptoms, take a preventive approach to disease, and see if your lifestyle changes or other interventions are reducing your risk factors and improving your health. Dr. Anjali Dsouza and Mike Haney discuss why biomarker testing can be beneficial, how to understand your levels, factors that affect your levels, and which biomarkers are no-brainers to get tested.Sign Up to Get Your Free Ultimate Guide to Glucose: ⁠⁠⁠⁠⁠⁠⁠https://levels.link/wnl⁠⁠⁠⁠⁠⁠Levels helps you see how food affects your health, empowering you with the tools needed to achieve health goals and improve healthspan. Levels Members gain access to the Levels app and continuous glucose monitors (CGMs), providing real-time feedback on how diet and lifestyle choices impact your metabolic health.Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.

Hosts Mitsuaki Sawano, MD, and co-hosts Kentaro Ejiri, MD, and Satoshi Shoji, MD, are joined by HFpEF expert Hidehiro Yaku, MD, from Northwestern University, for a deep dive into early treatment response to acoramidis, an amyloid stabilizer recently approved in Japan. They discuss its impact on serum transthyretin (sTTR) levels and the emerging role of sTTR as a dynamic biomarker of treatment efficacy. The episode explores the clinical relevance of early sTTR elevation, key insights from the ATTRibute-CM trial—including mediation and logistic regression analyses—and the use of waterfall plots to visualize treatment response. The team also compares acoramidis with tafamidis and vutrisiran, and looks ahead to the evolving therapeutic landscape of ATTR-CM, including gene editing and amyloid removal strategies.

Naked Gardening Best Cities… NJ Wildfire update and an arson arrest… AJ Brown car (whip) stolen… Jack in the Box closing hundreds of stores…Shannon Sharpe steps away from ESPN… NFL Draft Update… Email: ChewingTheFat@theblaze.com Sperm Race in LA… Blake Lively / Baldoni case ongoing... Golden Globes date... Academy rule changes…www.blazetv.com/jeffy Promo code Jeffy… Mortuary lady testing on bodies… No kidding, Jersey Mike's has new CEO… Game Show: What's The Lie? Family edition / Contestants: Dean & Wesley Castelhano… Learn more about your ad choices. Visit megaphone.fm/adchoices